It may be time for men to consider switching to Italian-style coffee as a means of reducing their risk of prostate cancer.
A recent study published in the International Journal of Cancer found that the consumption of this beverage has a protective effect on prostate cancer risk.
In an analysis of almost 7,000 men from Italy, those who consumed more than 3 cups a day showed a 53% reduction in prostate cancer disease risk when compared to men who had a daily 0-2 cups of coffee.
“Anyone who knows me well knows that I have always been a huge advocate for the positive health benefits drinking coffee provides”, explained Dr. David Samadi.
“We’ve known from many previous studies that coffee appears to have a protective effect against other health conditions such as heart disease and diabetes. The evidence on the effect of coffee consumption on prostate cancer are limited and this large study shines a light on the potential benefits of a common beverage consumed around the world on this common cancer in men.”
Prostate cancer remains one of the most common chronic diseases occurring in men particularly over the age of 50. Over the years it has been known that lifestyle modifications have demonstrated a positive impact on the prevention of this disease.
But the impact of coffee consumption on the incidence of the disease is still under debate. In the European Union, the country of Italy has one of the lowest incidences of prostate cancer in comparison to other populations from developed countries showing a higher prostate cancer occurrence.
This study wanted to research and evaluate the effect of Italian-style coffee consumption on prostate cancer risk to gain better knowledge of coffee’s influence on this disease.
Italian-style coffee is prepared unfiltered with high-pressure hot water temperature or boiling water that may result in less loss and a greater concentration of bioactive compounds that could be beneficial for reducing prostate cancer.
Coffee’s antitumor effect has also been shown in other types of cancer such as bladder, breast, colorectal, esophageal, pancreatic, and liver cancers”.